Editorial Comment
Another Piece of the Fish Oil Puzzle Gregory J. Dehmer, MD, FACC, FACP B eginning in the early part of this century, several arctic explorers made the observation that ischemic heart disease was a rare cause of death among the Eskimo population. More recent information indicates that ischemic heart disease represents only 3.5% of all deaths among Greenland Eskimos; this is nearly 10-fold less than that in Western countries. 1 The remarkably low incidence of ischemic heart disease among the Eskimos created an unsolved puzzle that sparked the interest of several investigators. Although early studies postulated a connection between the unique Eskimo diet and the low incidence of coronary artery disease, the epidemiological studies of Bang and See p 428 Dyerberg in the mid-1970s focused the greatest attention on this association.2 In contrast to a typical Western diet that contains predominantly the co-6 polyunsaturated fatty acids (PUFAs), the daily Eskimo diet includes substantial quantities of the co-3 PUFAs, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). These are derived from the large quantities of certain cold-water fish and mammals eaten by the Eskimos; hence, they are commonly referred to as the fish oils.
Initial in vitro evidence suggested that EPA had an antithrombotic effect,3 and this was verified by the finding of a prolonged bleeding time in Eskimos.' Also found was a marked decrease in platelet aggregation and, in some of the Eskimos examined, absent ADP and collagen-induced secondary phases of platelet aggregation. Furthermore, compared with the Danish control population, favorable alterations in serum lipids were found in the Eskimos. Summarizing their years of work, Bang and Dyerberg postulated that the altered lipid levels and hemostatic changes induced by the w-3 PUFAs were the potential cause for the low incidence of cardiovascular disease among the Eskimos.1,4
Since these early investigations, we have come to understand considerably more about the effects of the co-3 PUFAs. Thus, one-by-one, the pieces of this puzzle are fitting together. For example, changes in serum lipids and lipoproteins induced by the (0-3 PUFAs have now been well characterized.5 When large amounts of w-3 PUFAs are fed to normal volunteers or hyperlipemic patients, plasma cholesterol and triglyceride levels are lowered. When lower, more practical doses are used, the hypotriglyceridemic effect persists, but the changes in total serum cholesterol are more variable. Another prominent effect of the w-3 PUFAs is their ability to alter eicosanoid metabolism including both cyclooxygenase and lipoxygenase derivatives. The products of these metabolic pathways depend on the substrate available to these enzymes. In the typical US diet, the o-6 PUFA, linoleic acid is converted to arachidonic acid and subsequently via cyclooxygenase metabolism to thromboxane A2 (TXA2) in platelets and prostacyclin (PGI2) in vessel wall. These compounds have a pivotal role in the regulation of platelet aggregation and vascular tone. TXA2 has proaggregatory and vasoconstrictor activity,6 while PGI2 has the opposite effects. Normally, there tends to be a balance between these two agents.7 When cw-3 PUFAs are substituted or supplemented in the diet for w-6 PUFAs, several changes in eicosanoid metabolism occur. The cw-3 PUFAs inhibit the synthesis of arachidonic acid from linoleic acid,8 reduce the number of storage sites available for arachidonic acid,9 compete with the released arachidonic acid for cyclooxygenase,910 and inhibit the formation of certain hydroperoxides necessary to maintain the activity of cyclooxygenase."1 Lowering the concentration of arachidonic acid or cyclooxygenase activity would be expected to reduce the formation of both endothelial cell PGI2 and platelet TXA2. Although EPA is a poor substrate for cyclooxygenase compared with arachidonic acid,'2 it is oxidized to TXA3 and PGI3. TXA3 has little platelet proaggregatory activity, whereas PGI3 has moderate vasodilatory and antiaggregatory activity. The net result of these multiple effects of o-3 PUFAs is the inhibition of platelet aggregation and promotion of vasodilation, thereby substantially altering platelet-vessel wall interactions. Both arachidonic acid and EPA can be metabolized in the lipoxygenase pathway. In monocytes and neutrophils, substitution of the o-3 PUFAs results in the formation of leukotrienes of the 5 series rather than the 4 series, and these are considerably less effective in promoting chemotaxis and aggregation of neutrophils. 13 Several additional pieces of this puzzle have been identified, but their location in the picture is not yet clear. First, atherosclerosis is associated with endothelial injury and dysfunction, and this has been demonstrated to impair endothelium-dependent vascular relaxation. Dietary supplementation with codliver oil (an w-3 PUFA) has been shown to facilitate endothelium-dependent vascular responses in normal porcine coronary arteries and to improve these responses in atherosclerotic porcine coronary arteries.14,15 Similar effects have been shown in atherosclerotic monkeys16 and, most recently, in man. 17 Second, the incorporation of w-3 PUFAs into human erythrocyte phospholipids leads to increased red blood cell deformability and, consequently, to a decrease in whole blood, but not plasma, viscosity ex vivo in humans.9'18 It has been postulated that this will cause an improvement in oxygen delivery to areas of the myocardium supplied by stenotic vessels. Third, (o-3 PUFAs may increase endogenous fibrinolytic activity by two mechanisms. They can reduce the levels of inhibitors of tissue-type plasminogen activator (t-PA) (plasmin and a2-antiplasmin) and increase the levels of t-PA itself. 19 Finally, the fish oils can reduce the vasoconstrictor response to catecholamines and angiotensin,9 lower fibrinogen levels,20 and, in one animal model, markedly lower the incidence of ventricular fibrillation associated with coronary artery occlusion and reperfusion.21
In this issue of Circulation, DeCaterina et al provide another interesting piece of the fish oil puzzle.22 A moderate dose of wo-3 PUFAs was given to 15 patients for 28 days before coronary artery bypass surgery. Many of the effects documented, such as the changes in serum lipids, platelet membrane lipid composition, platelet aggregation, bleeding time, and serum TXB2 concentration, have been noted in earlier studies. However, tissue fragments from the atrium, aorta, and saphenous vein obtained at surgery in the patients treated with the w-3 PUFAs showed a greater spontaneous and stimulated production of PGI2 compared with a matched cohort of patients who did not receive such therapy. The finding of increased PGI2 production after w-3 PUFA administration differs from the results of some animal studies'0'1' and contrasts with what might be predicted from our current knowledge of the effects of these fatty acids. Despite the alterations in platelet function and the increased bleeding time, blood loss during and after surgery was not significantly different between the groups. Alterations in the urinary metabolites of prostacyclin after high-dose (10 g/day) co-3 PUFA administration have been evaluated in patients with atherosclerosis,23 but direct tissue measurements in humans have not been made previously. Although the mechanisms responsible for the increased PGI2 production were not defined, this observation broadens our understanding of the effects of the w,)-3 PUFAs on vessel walls.
When the fish oil puzzle finally is solved, we will have a clear picture of its role, if any, as a therapy for atherosclerosis and its complications. Results from several animal studies are encouraging, but it is not yet possible to extrapolate these results to humans. For example, Weiner et al showed in a porcine model that 30 ml/day cod-liver oil markedly diminished the coronary atherosclerosis induced by endothelial denudation and a high-cholesterol, high-fat diet.24 Similarly, fish oil treatment has been shown to inhibit the development of atherosclerosis in cholesterol-fed rabbits25 and nonhuman primates26 and to inhibit the development of intimal hyperplasia in a dog model of autogenous vein bypass grafts. 27 To date, the clinical situation most intensively studied in humans has been the use of the o-3 PUFAs for the prevention of restenosis after coronary angioplasty. [28] [29] [30] [31] [32] Of the five studies reported, three demonstrate a lower rate of restenosis in the treated patients. 28, 29, 32 The inconsistent results among these studies may be explained by important methodological differences between the individual studies. For example, therapy with the w-3 PUFAs was started at variable times before the angioplasty procedure in these studies; the longest pretreatment interval was 7 days,28 while in several studies therapy started within 24 hours of the procedure.29,30,32 When fish oil was started less than 1 day before or immediately after the procedure, favorable effects were reported in two studies29'32 but not in a third.30 As confirmed by DeCaterina et al,22 there are reasons to believe that therapy should be started well before the angioplasty procedure because many of the effects of the o-3 PUFAs are dependent on their incorporation into cell membranes. Generally, the time required to detect an effect on serum lipids, eicosanoid metabolism, or platelet-vessel wall interactions is measured in weeks rather than days. If the need for a substantial pretreatment phase is confirmed, the usefulness of this therapy in patients requiring more urgent angioplasty procedures will be negligible. Other important differences among the studies include the dose of fish oil, which varied from 2.7 to 6 g per day, and the different formulations that were used. In most of the studies, the fish oil was administered as a triglyceride form, but in one study,3' approximately one half of the treated patients received an ethylester form. This may, in part, explain the negative results in this study because the ethyl-ester form is poorly absorbed compared with the triglyceride and free fatty acid formulations.33'34 The findings of DeCaterina et al are noteworthy in that they emphasize the prominent effects of fish oil on vascular walls and prostacyclin production compared with their well-known but less potent antiplatelet effects. This observation suggests that these "vascular effects" may be of greater importance in the prevention of restenosis because it has been shown that more potent antiplatelet agents alone do not affect restenosis rates. Additional larger studies now in progress will confirm or refute these initial observations and determine whether the use of wo-3 PUFAs for restenosis will be part of the picture when the fish oil puzzle is finally completed.
The use of the w-3 PUFAs in patients recovering from acute myocardial infarction has recently been examined. 35 Subjects advised to eat fatty fish had a 29% reduction in mortality from all causes during the subsequent 2 years, which was completely explained by a reduction in deaths related to ischemic heart disease. However, the occurrence of reinfarction and other events related to ischemic heart disease was not significantly affected by the fatty fish diet. Whether this can be interpreted as evidence suggesting that fish oil results in smaller, more survivable infarcts in patients is unclear. This, too, is an interesting piece of the puzzle, but its location in the overall picture is as yet unknown.
Clearly, there is considerable interest in the actions of the co-3 PUFAs and their potential role as an intervention against the development and complications of atherosclerosis. At the present time, however, the clinical usefulness of the cw-3 PUFAs for such indications must be considered speculative. Perhaps stimulated by the increased "health consciousness" of our society, observations as to the possible health benefits of the w-3 PUFAs have kindled considerable interest among the general population. The combination of these speculated benefits, considerable consumer interest, and nonprescription availability has unfortunately provided the substrate for unsubstantiated claims as to their effects and long-term benefits. Nevertheless, the possibility of dietary fish oil supplementation as an intervention in the prevention of atherosclerosis or its thrombotic complications remains tempting and provocative. Certainly, it is very unlikely that we will determine that fish oil alone is the universal prevention for atherosclerosis. However, favorable effects, such as those demonstrated by DeCaterina et al,22 help to complete this puzzle and support the notion that these fatty acids could modify the occurrence and course of atherosclerosis. If well-designed clinical trials confirm this effect, dietary supplementation with the co-3 PUFAs could be one of the simplest and most valuable interventions against atherosclerosis and its complications.
